Canada Oligonucleotide Cdmo Market Size & Outlook, 2026-2033
The oligonucleotide cdmo market in Canada is expected to reach a projected revenue of US$ 100.9 million by 2033. A compound annual growth rate of 14.55% is expected of Canada oligonucleotide cdmo market from 2026 to 2033.
Revenue, 2025 (US$M)
$34.4
Estimate, 2026 (US$M)
$39.0
Forecast, 2033 (US$M)
$100.9
CAGR, 2026 - 2033
14.6%
Global Market
Related Markets
Canada oligonucleotide cdmo market highlights
- The Canada oligonucleotide cdmo market generated a revenue of USD 34.4 million in 2025 and is expected to reach USD 100.9 million by 2033.
- The Canada market is expected to grow at a CAGR of 14.55% from 2026 to 2033.
- In terms of segment, contract manufacturing was the largest revenue generating service in 2025.
- Contract Development is the most lucrative service segment registering the fastest growth during the forecast period.
Oligonucleotide cdmo market data book summary
| Market revenue in 2025 | USD 34.4 million |
| Market revenue in 2033 | USD 100.9 million |
| Growth rate | 14.55% (CAGR from 2026 to 2033) |
| Largest segment | Contract manufacturing |
| Fastest growing segment | Contract Development |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Contract Manufacturing, Contract Development |
| Key market players worldwide | PolyPeptide Group AG, STA Pharmaceutical, Bachem, Creative Peptides, Aurigene Pharmaceutical Services Ltd., Merck KGaA, Euroapi SA, Curia Global, Inc., CordenPharma, SYLENTIS |
Other key industry trends
- In terms of revenue, Canada accounted for 3.3% of the global oligonucleotide cdmo market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. oligonucleotide cdmo market is projected to lead the regional market in terms of revenue in 2033.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 989.8 million by 2033.
No credit card required*
Publish Date: Dec 10, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Oligonucleotide CDMO Market Scope
Oligonucleotide CDMO Market segmentation & scope
Oligonucleotide CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| PolyPeptide Group AG | View profile | 1,273 | Neuhofstrasse 24, Baar, Zug, Switzerland, 6340 | www.polypeptide.com |
| Euroapi SA | View profile | 3,326 | 15 rue Traversiere, Paris, France, 75012 | www.euroapi.com |
| SYLENTIS | View profile | 11-50 | Madrid, Madrid, Spain, Europe | www.sylentis.com |
| CordenPharma | View profile | 5001-10000 | Plankstadt, Baden-Wurttemberg, Germany, Europe | cordenpharma.com |
| Creative Peptides | View profile | 1-10 | New York, New York, United States, North America | www.creative-peptides.com/index.html |
| Aurigene Pharmaceutical Services Ltd. | View profile | - | - | - |
| Curia Global, Inc. | View profile | - | - | - |
| Bachem | View profile | 501-1000 | Bubendorf, Basel-Landschaft, Switzerland, Europe | www.bachem.com/ |
| STA Pharmaceutical | View profile | 5001-10000 | Shanghai, Shanghai, China, Asia | www.stapharma.com |
Canada Oligonucleotide CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Oligonucleotide CDMO Market Outlook will help companies and investors design strategic landscapes.
Contract Manufacturing was the largest segment with a revenue share of 71.8% in 2025.
Horizon Databook has segmented the Canada oligonucleotide cdmo market based on contract manufacturing, contract development covering the revenue growth of each sub-segment from 2021 to 2033.
- Canada Oligonucleotide Cdmo Market Service Outlook (Revenue, USD Million , 2021-2033)
- Contract Manufacturing
- Contract Development
- Canada Oligonucleotide Cdmo Market Type Outlook (Revenue, USD Million , 2021-2033)
- Antisense Oligonucleotides
- Small Interfering RNA
- Other Oligonucleotides
- Canada Oligonucleotide Cdmo Market Application Outlook (Revenue, USD Million , 2021-2033)
- Therapeutic
- Research
- Diagnostic
- Canada Oligonucleotide Cdmo Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceutical and Biopharmaceutical Companies
- Diagnostic Companies
- Others End Use
Reasons to subscribe to Oligonucleotide CDMO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Oligonucleotide CDMO Market Outlook databook
- Our clientele includes a mix of Oligonucleotide CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada Oligonucleotide CDMO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Oligonucleotide CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Canada Oligonucleotide Cdmo Market, 2021-2033 (US$M)
Canada oligonucleotide cdmo market statistics, by service, 2021-2033 (US$M)
